We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA - Free Report) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold or Sell?
Moderna stock has surged as much as 10% in Friday's trading session, reaching a fresh 52-week high of $267 a share after the biotechnology giant delivered much stronger-than-expected Q3 results.
The rally comes as investors increasingly gravitate toward healthcare stocks for defensive safety amid the broader technology selloff, with industry giants AbbVie and Eli Lilly recently reaching new highs as well.
However, with Moderna stock extending an extraordinary year-to-date rally of nearly 800%, investors may be wondering whether to chase the momentum or await a more attractive entry point.
Much of MRNA's remarkable surge has been fueled by positive Phase 3 melanoma trial results for its personalized cancer vaccine being developed with Merck, alongside improving financial performance and optimism surrounding its expanding vaccine portfolio.
Moderna's Q3 Earnings Crush Expectations
Moderna reported Q3 earnings of $0.38 per share, crushing expectations that called for a loss of $1.10 per share by 134% and reversing a loss of $0.51 in the year-ago quarter.
Quarterly revenue jumped 29% year over year to $1.31 billion, comfortably surpassing estimates of $889 million. Growth was primarily driven by stronger international COVID-19 vaccine sales, supported by long-term government supply agreements.
Encouragingly, Moderna generated $162 million in net income compared with a $200 million loss a year earlier, aided by a 27% reduction in research and development (R&D) expenses.
Moderna Provides Upbeat Guidance
Adding to the optimism, Moderna raised its full-year 2026 revenue growth outlook to 15%-25%, up from its previous forecast of up to 10% growth and ahead of Wall Street’s expectations of $2.1 billion in annual sales or 8% growth (Current Year Below).
Management also lowered its R&D spending outlook to approximately $2.7 billion from $2.9 billion.
Moderna's Valuation Raises Concerns After Massive Rally
Despite its impressive operating improvements, Moderna's valuation presents significant risks following its extraordinary YTD rally.
To that point, MRNA commands a market capitalization exceeding $100 billion and trades near 40X forward sales, an exceptionally rich premium for a biotechnology company still working toward sustainable profitability.
With Moderna remaining unprofitable over the last 12 months, traditional forward P/E comparisons are less useful, making its elevated price-to-sales multiple particularly concerning.
While the company's expanding pipeline offers substantial long-term potential, much of that optimism may already be reflected in its stock price.
Bottom Line: Buy, Hold, or Sell MRNA?
Moderna currently lands a Zacks Rank #3 (Hold), suggesting investors may want to avoid chasing the post-earnings spike despite the company's impressive Q3 results and improved outlook.
With MRNA extending its massive year-to-date rally, better buying opportunities could certainly be ahead. However, Moderna stock could become an ideal buy-the-dip target on a sharp pullback, particularly if its improving fundamentals and promising pipeline remain intact.
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
View the Zacks #1 Rank List
Image: Bigstock
Zacks Investment Ideas feature highlights: Moderna, AbbVie, Eli Lilly and Merck
For Immediate Release
Chicago, IL – November 9, 2026 – Today, Zacks Investment Ideas feature highlights Moderna (MRNA - Free Report) , AbbVie (ABBV - Free Report) , Eli Lilly (LLY - Free Report) and Merck (MRK - Free Report) .
Moderna (MRNA - Free Report) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold or Sell?
Moderna stock has surged as much as 10% in Friday's trading session, reaching a fresh 52-week high of $267 a share after the biotechnology giant delivered much stronger-than-expected Q3 results.
The rally comes as investors increasingly gravitate toward healthcare stocks for defensive safety amid the broader technology selloff, with industry giants AbbVie and Eli Lilly recently reaching new highs as well.
However, with Moderna stock extending an extraordinary year-to-date rally of nearly 800%, investors may be wondering whether to chase the momentum or await a more attractive entry point.
Much of MRNA's remarkable surge has been fueled by positive Phase 3 melanoma trial results for its personalized cancer vaccine being developed with Merck, alongside improving financial performance and optimism surrounding its expanding vaccine portfolio.
Moderna's Q3 Earnings Crush Expectations
Moderna reported Q3 earnings of $0.38 per share, crushing expectations that called for a loss of $1.10 per share by 134% and reversing a loss of $0.51 in the year-ago quarter.
Quarterly revenue jumped 29% year over year to $1.31 billion, comfortably surpassing estimates of $889 million. Growth was primarily driven by stronger international COVID-19 vaccine sales, supported by long-term government supply agreements.
Encouragingly, Moderna generated $162 million in net income compared with a $200 million loss a year earlier, aided by a 27% reduction in research and development (R&D) expenses.
Moderna Provides Upbeat Guidance
Adding to the optimism, Moderna raised its full-year 2026 revenue growth outlook to 15%-25%, up from its previous forecast of up to 10% growth and ahead of Wall Street’s expectations of $2.1 billion in annual sales or 8% growth (Current Year Below).
Management also lowered its R&D spending outlook to approximately $2.7 billion from $2.9 billion.
Moderna's Valuation Raises Concerns After Massive Rally
Despite its impressive operating improvements, Moderna's valuation presents significant risks following its extraordinary YTD rally.
To that point, MRNA commands a market capitalization exceeding $100 billion and trades near 40X forward sales, an exceptionally rich premium for a biotechnology company still working toward sustainable profitability.
With Moderna remaining unprofitable over the last 12 months, traditional forward P/E comparisons are less useful, making its elevated price-to-sales multiple particularly concerning.
While the company's expanding pipeline offers substantial long-term potential, much of that optimism may already be reflected in its stock price.
Bottom Line: Buy, Hold, or Sell MRNA?
Moderna currently lands a Zacks Rank #3 (Hold), suggesting investors may want to avoid chasing the post-earnings spike despite the company's impressive Q3 results and improved outlook.
With MRNA extending its massive year-to-date rally, better buying opportunities could certainly be ahead. However, Moderna stock could become an ideal buy-the-dip target on a sharp pullback, particularly if its improving fundamentals and promising pipeline remain intact.
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Get all the details here >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.